Orexin-2 Receptor Agonists for Narcolepsy Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for narcolepsy primarily address symptoms rather than the root cause, and there is a need for pharmacotherapeutics that can modulate orexin signaling effectively to treat narcolepsy and other disorders associated with orexin insufficiency, such as Parkinson's disease, Alzheimer's disease, and traumatic brain injury, which require improved compounds with enhanced physicochemical, pharmacological, and pharmaceutical properties.
Innovation Solution
Development of 2-(3-ethynylbenzyl)-substituted heterocycle derivatives and their pharmaceutically acceptable salts that modulate orexin-2 receptor activity, offering improved bioavailability and binding affinity for arousal-state regulating neurons, which can be administered via various routes including oral and intranasal, to stimulate wakefulness and treat related disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current symptomatic treatments are used for narcolepsy, then symptom management is achieved, but the root cause (orexin insufficiency) remains untreated
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of orexin receptor agonists through systematic variation of substituents at specific positions (R1, R2, R3, R4, R5, R6) on the benzene ring and heterocyclic moieties. This structural optimization enhances binding affinity to OX2R and improves pharmacokinetic properties including oral bioavailability, brain penetration, and metabolic stability, thereby addressing both effectiveness and developability
Solution Approach 2:
The patent employs composite molecular structures combining multiple functional elements: a core heterocyclic system (pyrrolidine, piperidine, morpholine, etc.), aromatic substituents (phenyl, naphthyl, heteroaryl), and various functional groups (alkoxy, amino, halo, cyano). This composite approach creates molecules with optimized properties for selective OX2R activation while maintaining desirable pharmacokinetic characteristics
2Reliability
If existing OX2R agonists are administered, then some wakefulness promotion is achieved, but bioavailability and binding affinity are insufficient
Solution Approach 1:
The patent applies local quality by introducing specific substituents at defined positions on the molecular scaffold. For example, electron-withdrawing groups (halo, cyano, nitro) or electron-donating groups (alkoxy, amino) are placed at specific aromatic positions to modulate electron density and enhance interactions with key residues in the OX2R binding pocket, thereby improving binding affinity without requiring global structural complexity
Solution Approach 2:
The patent incorporates dynamic elements through flexible linkers (alkylene chains, oxyalkylene groups) and rotatable bonds that allow the molecule to adopt optimal conformations for receptor binding. This dynamic flexibility enables the compound to adapt its shape upon receptor interaction, enhancing binding affinity while maintaining a relatively simple core structure
3Reliability
If alternative routes of administration are used, then brain penetration is improved, but administration complexity increases
Solution Approach 1:
The patent optimizes physicochemical parameters including molecular weight (keeping compounds within drug-like ranges), lipophilicity (balancing LogP for membrane permeability), and hydrogen bonding capacity (controlling H-bond donors and acceptors). These parameter optimizations enable the compounds to achieve adequate brain penetration via oral administration, eliminating the need for complex alternative routes while maintaining central nervous system efficacy
Data Source
AI summary
The present disclosure relates to compounds of Formula (I):and to their prodrugs, pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are useful for modulating orexin-2 receptor activity and may be used in the treatment of disorders in which orexin-2 receptor activity is implicated, such as a neurodegenerative disorder, a symptom of a rare genetic disorder, a mental health disorder, a metabolic syndrome, osteoporosis, cardiac failure, coma, or a complication in emergence from anaesthesia.